153 related articles for article (PubMed ID: 36331258)
21. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
Zhang D; Goldberg MV; Chiu ML
J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibody-mediated killing of tumour cells by neutrophils.
Heemskerk N; van Egmond M
Eur J Clin Invest; 2018 Nov; 48 Suppl 2(Suppl Suppl 2):e12962. PubMed ID: 29855035
[TBL] [Abstract][Full Text] [Related]
23. Human Tumor-Associated Macrophages and Neutrophils Regulate Antitumor Antibody Efficacy through Lethal and Sublethal Trogocytosis.
Singhal S; Rao AS; Stadanlick J; Bruns K; Sullivan NT; Bermudez A; Honig-Frand A; Krouse R; Arambepola S; Guo E; Moon EK; Georgiou G; Valerius T; Albelda SM; Eruslanov EB
Cancer Res; 2024 Apr; 84(7):1029-1047. PubMed ID: 38270915
[TBL] [Abstract][Full Text] [Related]
24. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy.
Valerius T; Repp R; de Wit TP; Berthold S; Platzer E; Kalden JR; Gramatzki M; van de Winkel JG
Blood; 1993 Aug; 82(3):931-9. PubMed ID: 7687898
[TBL] [Abstract][Full Text] [Related]
25. Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo.
Wallace PK; Kaufman PA; Lewis LD; Keler T; Givan AL; Fisher JL; Waugh MG; Wahner AE; Guyre PM; Fanger MW; Ernstoff MS
J Immunol Methods; 2001 Feb; 248(1-2):167-82. PubMed ID: 11223077
[TBL] [Abstract][Full Text] [Related]
26. Distinct functions of surface receptors in the induction of neutrophil-mediated cytotoxicity.
Cordier G; Samarut C; Revillard JP
Ann Immunol (Paris); 1981; 132D(1):3-14. PubMed ID: 7347555
[TBL] [Abstract][Full Text] [Related]
27. Interferon-gamma enhances monoclonal antibody 17-1A-dependent neutrophil cytotoxicity toward colorectal carcinoma cell line SW11-16.
Reali E; Guiliani AL; Spisani S; Moretti S; Gavioli R; Masucci G; Gambari R; Traniello S
Clin Immunol Immunopathol; 1994 Apr; 71(1):105-12. PubMed ID: 8137553
[TBL] [Abstract][Full Text] [Related]
28. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity.
Kushner BH; Cheung NK
Blood; 1992 Mar; 79(6):1484-90. PubMed ID: 1347707
[TBL] [Abstract][Full Text] [Related]
29. Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells.
Treffers LW; Zhao XW; van der Heijden J; Nagelkerke SQ; van Rees DJ; Gonzalez P; Geissler J; Verkuijlen P; van Houdt M; de Boer M; Kuijpers TW; van den Berg TK; Matlung HL
Eur J Immunol; 2018 Feb; 48(2):344-354. PubMed ID: 28952147
[TBL] [Abstract][Full Text] [Related]
30. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
Duchemin M; Khamassi M; Xu L; Tudor D; Bomsel M
Front Immunol; 2018; 9():244. PubMed ID: 29651286
[TBL] [Abstract][Full Text] [Related]
31. Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils.
Behrens LM; van den Berg TK; van Egmond M
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884427
[TBL] [Abstract][Full Text] [Related]
32. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
Pereira NA; Chan KF; Lin PC; Song Z
MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
[TBL] [Abstract][Full Text] [Related]
33. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis.
Metelitsa LS; Gillies SD; Super M; Shimada H; Reynolds CP; Seeger RC
Blood; 2002 Jun; 99(11):4166-73. PubMed ID: 12010822
[TBL] [Abstract][Full Text] [Related]
34. Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner.
Mullarkey CE; Bailey MJ; Golubeva DA; Tan GS; Nachbagauer R; He W; Novakowski KE; Bowdish DM; Miller MS; Palese P
mBio; 2016 Oct; 7(5):. PubMed ID: 27703076
[TBL] [Abstract][Full Text] [Related]
35. Neutrophils mediate HIV-specific antibody-dependent phagocytosis and ADCC.
Worley MJ; Fei K; Lopez-Denman AJ; Kelleher AD; Kent SJ; Chung AW
J Immunol Methods; 2018 Jun; 457():41-52. PubMed ID: 29605231
[TBL] [Abstract][Full Text] [Related]
36. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
37. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
[TBL] [Abstract][Full Text] [Related]
38. Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA.
Cottignies-Calamarte A; Tudor D; Bomsel M
Front Immunol; 2023; 14():1037033. PubMed ID: 36817447
[TBL] [Abstract][Full Text] [Related]
39. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
40. Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody.
Gehlert CL; Rahmati P; Boje AS; Winterberg D; Krohn S; Theocharis T; Cappuzzello E; Lux A; Nimmerjahn F; Ludwig RJ; Lustig M; Rösner T; Valerius T; Schewe DM; Kellner C; Klausz K; Peipp M
Front Immunol; 2022; 13():957874. PubMed ID: 36119088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
